Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Molecular Mechanisms and Therapy for Heart Valve Diseases
share announcement

Molecular Mechanisms and Therapy for Heart Valve Diseases

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 1402

Special Issue Editors

Dr. Eva Jover García

E-Mail Website
Guest Editor
Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), 31008 Pamplona, Spain
Interests: atherosclerosis; valve heart disease; biomarkers; cell signalling; molecular biology; ncRNAs; epigenetics; therapeutics; cardiovascular biology; tissue engineering
Dr. Ernesto Martín-Núñez

E-Mail Website
Guest Editor
Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), 31008 Pamplona, Spain
Interests: valve heart disease; aortic stenosis; diabetes; atherosclerosis; renal disease; α-Klotho; ageing; epigenetics; molecular biology; cell signalling
Dr. Jaime Ibarrola

E-Mail Website
Guest Editor
Molecular Cardiology Research Institute, Tufts Medical Center, 800 Washington Box 80 St. 5th Fl, Boston, MA 02111, USA
Interests: vascular aging; sex differences; therapeutic targets; cell crosstalk; cardiovascular diseases; vascular stiffness; epigenetics

Special Issue Information

Dear Colleagues,

Heart valve disease (HVD) is a major form of cardiovascular disease and is strongly prevalent in the elderly. Owing to the continuum ageing of the population, HVD is anticipated to become the next cardiac epidemic. With long preclinical stages, the onset of symptoms stands as a poor prognosis marker. After more than 30 years of research we have now some clues on how the valves are damaged. Highly multifactorial and complex cues trigger molecular, cellular, and interstitial events. Resident valvular cells, and others recruited within the damaged valve, are pivotal to the HVD. Nevertheless, identifying druggable targets is yet an unmet clinical need and valvular replacement remains the current therapeutic choice, regardless of limitations. Moreover, accumulating evidence suggest sex-related differences underlying the pathogenesis of HVD, seemingly impacting the clinical prognosis and management of the patients. Yet, female sex remains overlooked. Revisiting our current knowledge in HVD is strongly advised.

In the era of multi-omics and high-throughput pharmacological screenings, a spike of novel targets, biomarkers, and drugs are expected. It is our task to identify, standardize, and implement appropriate HVD models and clinical studies for target validation and drug testing. The aim of this Special Issue is to gather interdisciplinary, meaningful, and provoking research contributions (e.g., basic, translational, or clinical) on molecular and cellular mechanisms, novel therapies, and diagnosis/prognosis tools in HVD. A special focus, but not exclusive, will be given to the study of sex-related differences in HVD. Original research, brief research, methodological studies, and reviews are welcomed.

Dr. Eva Jover García
Dr. Ernesto Martín-Núñez
Dr. Jaime Ibarrola
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • valvular heart disease
  • sexual dimorphism
  • experimental modelling
  • cell signalling
  • molecular biology
  • epigenetics
  • biomarkers
  • diagnostics
  • tissue engineering
  • therapeutics

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1835 KiB  
Article
Specific Multiomic Profiling in Aortic Stenosis in Bicuspid Aortic Valve Disease
by Borja Antequera-González, Neus Martínez-Micaelo, Carlos Sureda-Barbosa, Laura Galian-Gay, M. Sol Siliato-Robles, Carmen Ligero, Artur Evangelista and Josep M. Alegret
Biomedicines 2024, 12(2), 380; https://doi.org/10.3390/biomedicines12020380 - 6 Feb 2024
Viewed by 827
Abstract
Introduction and purpose: Bicuspid aortic valve (BAV) disease is associated with faster aortic valve degeneration and a high incidence of aortic stenosis (AS). In this study, we aimed to identify differences in the pathophysiology of AS between BAV and tricuspid aortic valve (TAV) [...] Read more.
Introduction and purpose: Bicuspid aortic valve (BAV) disease is associated with faster aortic valve degeneration and a high incidence of aortic stenosis (AS). In this study, we aimed to identify differences in the pathophysiology of AS between BAV and tricuspid aortic valve (TAV) patients in a multiomics study integrating metabolomics and transcriptomics as well as clinical data. Methods: Eighteen patients underwent aortic valve replacement due to severe aortic stenosis: 8 of them had a TAV, while 10 of them had a BAV. RNA sequencing (RNA-seq) and proton nuclear magnetic resonance spectroscopy (1H-NMR) were performed on these tissue samples to obtain the RNA profile and lipid and low-molecular-weight metabolites. These results combined with clinical data were posteriorly compared, and a multiomic profile specific to AS in BAV disease was obtained. Results: H-NMR results showed that BAV patients with AS had different metabolic profiles than TAV patients. RNA-seq also showed differential RNA expression between the groups. Functional analysis helped connect this RNA pattern to mitochondrial dysfunction. Integration of RNA-seq, 1H-NMR and clinical data helped create a multiomic profile that suggested that mitochondrial dysfunction and oxidative stress are key players in the pathophysiology of AS in BAV disease. Conclusions: The pathophysiology of AS in BAV disease differs from patients with a TAV and has a specific RNA and metabolic profile. This profile was associated with mitochondrial dysfunction and increased oxidative stress. Full article
(This article belongs to the Special Issue Molecular Mechanisms and Therapy for Heart Valve Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop